How the US Section 301 Probe Targets Germany's Drug Pricing

The US has opened a formal trade investigation into how Germany prices medicines, and the outcome could ripple far beyond Berlin. Drugmakers have already signaled they may delay or withdraw product launches in Germany over pending legislation, and a tariff threat now sits on top of that uncertainty.¹

The investigation, opened under Section 301 of the Trade Act, targets Germany's health insurance cost containment measures, which the US argues amount to persistent underpayment for medicines.¹ If the process advances, it could result in tariffs on German pharmaceutical exports to the US, including active pharmaceutical ingredients and finished-dose products.¹

Why Is the US Targeting Germany's Drug Pricing Now?

US Trade Representative Jamieson Greer announced the probe, framing it as a response to an uneven global split of pharmaceutical research and development costs.¹ In a press release announcing the investigation, Greer said President Trump has made clear that American patients "should not be shouldering a disproportionate share of global pharmaceutical research and development."¹ He pointed specifically to draft German legislation that would fast track additional manufacturer discounts into the country's public health insurance funds, a measure that has already led several drugmakers to warn they may withdraw or delay launches in the country.¹ Germany introduced the broader health insurance overhaul in April as part of a push to control rising public health spending, and the legislation is still moving through parliamentary review, with no final policy yet enacted.¹

Greer left open the possibility of a negotiated resolution rather than tariffs, pointing to a recent agreement with the UK in which the National Health Service committed to paying higher prices for innovative medicines in exchange for a tariff exemption.¹

What Would Tariffs Mean for German Pharmaceutical Exports?

Germany is one of Europe's most significant pharmaceutical manufacturing nations, home to major development and production operations for Bayer, Boehringer Ingelheim, and Merck KGaA, along with a substantial contract manufacturing presence.¹ If tariffs are imposed on US-bound German pharmaceutical products, including APIs and finished-dose forms, the cost structure of that manufacturing corridor could shift considerably.¹

A public hearing on the matter is expected in September, leaving a sustained period of ambiguity for any organization with German manufacturing exposure in the meantime.¹

How Does This Connect to the Administration's Broader Pricing Agenda?

The investigation carries a broader signal about where pharmaceutical capital is likely to flow, a connection the administration has drawn explicitly between European reference pricing policies and reduced investment in pharmaceutical innovation, tracked through plant expansion decisions, technology transfer activity, and contract manufacturing capacity announcements.¹

This probe follows the Trump administration's most favored nation (MFN) pricing policy, which ties US drug prices to lower international benchmarks and has already prompted 17 major pharmaceutical companies to make voluntary price concessions in exchange for tariff exemptions.¹ Critics have argued those policies reduce the financial returns that underwrite new drug development, and the Germany investigation extends that same pressure to a foreign pricing system directly.¹

Why Does Germany's Pricing Structure Matter to the MFN Framework?

The Section 301 probe is one piece of a larger US drug pricing strategy built around the MFN framework, which the White House Council of Economic Advisers projects could generate roughly $529 billion in cumulative domestic savings over a decade.² The policy applies a net price methodology, accounting for rebates, discounts, and other concessions rather than list prices, specifically to prevent reference countries from circumventing fair-share contributions through confidential discount arrangements.²

Germany is directly implicated in that framework. Its existing drug pricing arbitration structure already requires manufacturers to submit net pricing data from reference countries, and the Council of Economic Advisers cited that exact structure as a model for how the MFN reporting methodology was designed.² That history is part of why Germany's current cost containment push is drawing this level of scrutiny from US trade officials, with implications that extend well beyond bilateral trade and into how the global revenue base supporting drug development gets restructured in the years ahead.²

References

1. CNBC. U.S. Opens Tariff Probe Targeting Germany's Drug Pricing Policies. Published June 19, 2026. https://www.cnbc.com/2026/06/19/us-tariff-probe-germany-drug-pricing-policies-mfn.html
2. U.S. White House Council of Economic Advisers. Savings from Most-Favored-Nation Drug Pricing Policy. Press Release. May 4, 2026. https://www.whitehouse.gov/research/2026/05/savings-from-most-favored-nation-drug-pricing-policy/